Headlines about La Jolla Pharmaceutical (NASDAQ:LJPC) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.8771149935501 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- La Jolla Pharmaceutical Company (LJPC) Analysts See $-1.46 EPS (nmsuherald.com)
- Recent Analysts Moves of Stock: La Jolla Pharmaceutical Company (LJPC) (nasdaqexpress.com)
- La Jolla Pharmaceutical (LJPC) Rating Reiterated by Jefferies Group (americanbankingnews.com)
- La Jolla Pharmaceutical (LJPC) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- EPS for La Jolla Pharmaceutical Company (LJPC) forecasted at $-1.46 (thecasualsmart.com)
La Jolla Pharmaceutical stock opened at $31.01 on Tuesday. La Jolla Pharmaceutical has a 12-month low of $22.68 and a 12-month high of $41.36. The firm has a market cap of $808.92, a P/E ratio of -5.73 and a beta of 1.36.
A number of equities analysts have recently commented on LJPC shares. BidaskClub raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Chardan Capital reaffirmed a “buy” rating and set a $90.00 price target on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. SunTrust Banks reaffirmed a “buy” rating and set a $65.00 price target (down previously from $67.00) on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Cowen reaffirmed a “buy” rating and set a $55.00 price target on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Finally, ValuEngine downgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Monday, April 2nd. Three analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $55.86.
In related news, major shareholder Life Sciences Maste Perceptive bought 175,000 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was bought at an average price of $32.72 per share, with a total value of $5,726,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Perceptive Advisors Llc bought 700,000 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was bought at an average cost of $29.50 per share, with a total value of $20,650,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,544,474 shares of company stock worth $46,485,863 in the last ninety days. 25.47% of the stock is currently owned by insiders.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.